Equities

RaySearch Laboratories AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert

RaySearch Laboratories AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)181.40
  • Today's Change0.80 / 0.44%
  • Shares traded207.40k
  • 1 Year change-28.44%
  • Beta1.0065
Data delayed at least 15 minutes, as of Feb 10 2026 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

RaySearch Laboratories AB (publ) is a Sweden-based medical technology company that develops software for radiation therapy of cancer. It markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.

  • Revenue in SEK (TTM)1.29bn
  • Net income in SEK219.17m
  • Incorporated1988
  • Employees450.00
  • Location
    RaySearch Laboratories AB (publ)Eugeniavagen 18CSTOCKHOLM 104 30SwedenSWE
  • Phone+46 851053000
  • Fax+46 854506139
  • Websitehttps://www.raysearchlabs.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CellaVision AB748.45m151.41m3.78bn230.0024.994.4419.925.056.356.3531.3835.700.72662.036.123,171,403.0014.7014.5916.8117.1069.1168.0520.2319.642.4327.890.03138.496.789.397.997.2533.00--
COLTENE Holding AG2.80bn166.68m3.81bn1.18k22.843.6115.521.362.402.4040.2215.131.311.346.40204,684.507.8010.5914.2618.4366.1162.195.957.640.70437.620.360685.663.06-1.7971.310.4306-15.4510.76
Medistim ASA622.85m132.68m3.83bn154.0028.769.7824.316.147.797.7936.5622.911.250.76799.674,341,637.0026.7221.9833.0927.1981.2178.6621.3020.322.03--0.048485.046.889.120.00878.1112.5316.89
IVF Hartmann Holding AG1.86bn221.46m4.14bn309.0018.692.4414.682.237.927.9266.3960.570.89643.287.88526,221.1010.697.9012.919.6855.7154.0611.939.133.79--0.004248.547.332.8534.0210.78-28.9419.92
Ion Beam Applications SA6.34bn180.74m4.76bn2.10k26.073.6515.210.75120.56770.567720.174.060.97562.733.28281,693.602.781.5012.034.6431.2134.392.852.150.62097.410.363170.816.7512.01201.573.997.6925.86
Lumibird SA2.30bn114.03m5.49bn1.07k48.172.5816.982.390.47750.47759.618.900.50770.95934.42202,198.502.522.513.113.1763.8961.894.974.901.643.160.45830.001.7513.34-20.08-8.3815.27--
RaySearch Laboratories AB (publ)1.29bn219.17m5.56bn450.0028.256.7311.494.316.396.3937.6926.820.65234.152.843,104,637.0011.072.9616.314.3792.9690.9316.975.801.55--0.30967.9016.629.96149.4932.190.5132--
Revenio Group Oyj1.16bn196.62m5.60bn248.0028.514.8223.144.840.69310.69314.084.100.80872.916.94452,352.7013.6514.1115.7517.5371.8670.9616.8820.611.8010.720.103653.127.1915.91-3.2014.6422.935.92
medmix AG5.45bn-67.54m5.66bn2.67k--1.139.981.04-0.1696-0.169611.6010.390.47073.565.86174,403.90-0.49271.27-0.61991.5534.5235.24-1.052.651.101.870.4268140.79-0.55492.84-2,566.67--6.02--
Advanced Medical Solutions Group plc2.69bn111.45m5.82bn1.50k52.051.8615.682.160.04170.04171.011.170.57582.095.57137,690.002.385.092.635.5252.1955.064.1411.151.553.880.242833.4740.6611.64-55.35-17.818.3610.90
Xvivo Perfusion AB812.17m25.16m6.10bn198.00243.112.8963.987.510.79680.796825.7667.100.340.89396.134,101,844.001.053.281.123.5273.8173.863.1010.873.681.830.05570.00-1.2535.19-85.39------
Synektik SA1.33bn239.05m6.41bn203.0026.8311.3923.814.8211.099.2061.8026.121.2211.183.60--21.9620.1136.1032.6734.9831.4017.9513.601.4142.090.153--9.1640.2951.5870.0228.82--
Arjo AB (publ)11.00bn334.00m6.81bn6.94k21.840.97824.770.61871.231.2340.3927.380.7044.926.221,584,702.002.143.262.914.8042.5943.423.044.780.84944.190.417948.74-2.593.92-32.93-8.68--2.25
GVS SpA4.49bn243.06m8.26bn4.23k31.031.8011.411.840.13230.13232.352.280.4752.027.0199,768.772.576.013.338.5356.1157.985.4111.160.75672.400.4234--0.895913.51144.520.172923.38--
Data as of Feb 10 2026. Currency figures normalised to RaySearch Laboratories AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

35.53%Per cent of shares held by top holders
HolderShares% Held
Swedbank Robur Fonder ABas of 19 Mar 20252.06m7.20%
Premier Fund Managers Ltd.as of 30 Sep 20251.32m4.60%
Andra AP-fondenas of 31 Dec 20241.22m4.27%
Financi�re de l'�chiquier SAas of 31 Mar 20251.03m3.59%
Deka Investment GmbHas of 30 Sep 20251.02m3.55%
Case Kapitalf�rvaltning ABas of 30 Jan 2026894.15k3.12%
American Century Investment Management, Inc.as of 08 Jan 2026888.64k3.10%
Herald Investment Management Ltd.as of 31 Dec 2024690.89k2.41%
Dimensional Fund Advisors LPas of 08 Jan 2026595.92k2.08%
Amundi Asset Management SASU (Investment Management)as of 07 Jan 2026456.31k1.59%
More ▼
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.